Supporting Innovative ALS Treatments with Clene Nanomedicine & Synapticure
October 14, 2024
Anovo is proud to announce a new partnership with Clene Nanomedicine, Inc. and Synapticure Inc., supporting their efforts to bring hope to people living with Amyotrophic Lateral Sclerosis (ALS). As part of this collaboration, Anovo is now dispensing CNM-Au8®, Clene’s innovative gold nanocrystal suspension, for their Early Access Program (EAP) patients.
What is Amyotrophic Lateral Sclerosis (ALS)?
ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. Over time, the disease leads to a loss of muscle control and function, often impacting the ability to move, speak, swallow, and even breathe. The disease has a profound impact on patients and their families, making the search for innovative therapies like CNM-Au8® critical.
Clene Nanomedicine and Synapticure Partner with Anovo
Our collaboration with Clene Nanomedicine and Synapticure underscores our dedication to improving access to promising therapies. By dispensing this treatment through Clene’s Early Access Program, Anovo is helping to ensure patients and families receive the care and support they need to navigate the challenges of ALS.
Related Posts
How Anovo Builds Dedicated Teams to Support Your Rare Disease Therapy
At Anovo, we understand that complex rare disease therapies require high-touch service that large payer- and Pharmacy Benefit Manager-owned Specialty…
January 30, 2025
Justin’s Story: Living with Duchenne Muscular Dystrophy
When Justin was first diagnosed with Duchenne muscular dystrophy, his parents, Amanda and Andrew, weren’t sure how to navigate the…
January 14, 2025
Eton Pharmaceuticals & Anovo Partner to Expand Access for Patients with Severe Primary Insulin-Like Growth Factor 1 Deficiency
Eton Pharmaceuticals is dedicated to developing and commercializing treatments for rare diseases, with a strong focus on pediatric endocrinology. Their…
December 20, 2024
